Lentigen Technology Inc., a subsidiary of Miltenyi Biotec GmbH, announced today its acquisition of immunotherapy start-up Living Pharma, Inc. Eduardo Davila, PhD, Living Pharma Co-Founder and Chief Scientific Officer, who is also a faculty member of the University of Maryland School of Medicine (UMSOM), along with Koji Tamada, MD, PhD, UMSOM, invented Living Pharma’s anti-tag-chimeric antigen receptor (AT-CAR™) technology.
{iframe}https://globenewswire.com/news-release/2017/07/20/1054651/0/en/Lentigen-Technology-Inc-a-Miltenyi-Biotec-Company-Acquires-University-of-Maryland-Baltimore-CAR-T-Cell-Start-Up-Living-Pharma-Inc.html{/iframe}